Literature DB >> 33128075

The diagnostic value of phase angle, an integrative bioelectrical marker, for identifying individuals with dysmobility syndrome: the Korean Urban-Rural Elderly study.

Y W Jung1, N Hong2, C O Kim3, H C Kim4, Y Youm5, J -Y Choi6, Y Rhee1.   

Abstract

Low phase angle, a non-invasive bioimpedance marker, is associated with elevated odds of dysmobility syndrome and its components. Phase angle (estimated cutoffs: < 4.8° in men; < 4.5° in women) can be used to detect dysmobility syndrome in community-dwelling older adults as a simple, integrative screening tool.
INTRODUCTION: Dysmobility syndrome uses a score-based approach to predict fracture risk that incorporates the concepts of osteoporosis, sarcopenia, and obesity. Low phase angle (PhA), a simple, non-invasive bioelectrical impedance marker, was associated with low lean mass, high fat mass, and poor muscle function. We aimed to investigate the association between PhA and dysmobility syndrome, with the exploration of the diagnostic cutoffs.
METHODS: In a community-dwelling Korean older adult cohort, dysmobility syndrome was defined as the presence of ≥ 3 of the following components: osteoporosis, low lean mass, falls in the preceding year, low grip strength, high fat mass, and poor timed up and go performance.
RESULTS: Among the 1825 participants (mean age 71.6, women 66.7%), subjects were classified into sex-stratified PhA tertiles. The prevalence of dysmobility syndrome increased from the highest PhA tertile group to the lowest (15.50 to 2.45% in men; 33.41 to 12.25% in women, P for trend < 0.001). The mean PhA values decreased as the dysmobility score increased (5.33° to 4.65° in men; 4.76° to 4.39° in women, P for trend < 0.001). Low PhA (cutoff: < 4.8° in men; < 4.5° in women) was associated with twofold elevated odds of dysmobility syndrome after adjusting for age, sex, and conventional risk factors. Low PhA improved the identification of individuals with dysmobility syndrome when added to the conventional risk model (area under the curve, 0.73 to 0.75, P = 0.002).
CONCLUSION: Low PhA was associated with dysmobility syndrome and its components, independent of age, sex, body mass index, nutritional status, and inflammation.

Entities:  

Keywords:  Aging; Bioelectric impedance analysis; Falls; Obesity; Osteoporosis; Sarcopenia

Year:  2020        PMID: 33128075     DOI: 10.1007/s00198-020-05708-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

1.  Dysmobility Syndrome Independently Increases Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Prospective Cohort Study.

Authors:  Bjoern Buehring; Karen E Hansen; Brian L Lewis; Steven R Cummings; Nancy E Lane; Neil Binkley; Kristine E Ensrud; Peggy M Cawthon
Journal:  J Bone Miner Res       Date:  2018-06-21       Impact factor: 6.741

2.  Bioelectrical impedance analysis: population reference values for phase angle by age and sex.

Authors:  Maria Cristina G Barbosa-Silva; Aluísio J D Barros; Jack Wang; Steven B Heymsfield; Richard N Pierson
Journal:  Am J Clin Nutr       Date:  2005-07       Impact factor: 7.045

3.  Bioelectric impedance phase angle and body composition.

Authors:  R N Baumgartner; W C Chumlea; A F Roche
Journal:  Am J Clin Nutr       Date:  1988-07       Impact factor: 7.045

Review 4.  What's in a name revisited: should osteoporosis and sarcopenia be considered components of "dysmobility syndrome?".

Authors:  N Binkley; D Krueger; B Buehring
Journal:  Osteoporos Int       Date:  2013-08-01       Impact factor: 4.507

5.  Dysmobility syndrome and mortality risk in US men and women age 50 years and older.

Authors:  A C Looker
Journal:  Osteoporos Int       Date:  2014-10-09       Impact factor: 4.507

6.  Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study.

Authors:  Marjolein Visser; Stephen B Kritchevsky; Bret H Goodpaster; Anne B Newman; Michael Nevitt; Elizabeth Stamm; Tamara B Harris
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

7.  Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study.

Authors:  Francesco Landi; Alfonso J Cruz-Jentoft; Rosa Liperoti; Andrea Russo; Silvia Giovannini; Matteo Tosato; Ettore Capoluongo; Roberto Bernabei; Graziano Onder
Journal:  Age Ageing       Date:  2013-01-15       Impact factor: 10.668

Review 8.  Obesity and fracture risk.

Authors:  Stefano Gonnelli; Carla Caffarelli; Ranuccio Nuti
Journal:  Clin Cases Miner Bone Metab       Date:  2014-01

9.  BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.

Authors:  Katie L Stone; Dana G Seeley; Li-Yung Lui; Jane A Cauley; Kristine Ensrud; Warren S Browner; Michael C Nevitt; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

10.  Dysmobility syndrome is associated with prevalent morphometric vertebral fracture in older adults: the Korean Urban-Rural Elderly (KURE) study.

Authors:  Namki Hong; Chang Oh Kim; Yoosik Youm; Jin-Young Choi; Hyeon Chang Kim; Yumie Rhee
Journal:  Arch Osteoporos       Date:  2018-08-14       Impact factor: 2.617

View more
  2 in total

1.  Computed Tomography-Derived Skeletal Muscle Radiodensity Predicts Peak Weight-Corrected Jump Power in Older Adults: The Korean Urban Rural Elderly (KURE) Study.

Authors:  Heewon Choi; Namki Hong; Narae Park; Chang Oh Kim; Hyeon Chang Kim; Jin Young Choi; Yoosik Youm; Yumie Rhee
Journal:  Calcif Tissue Int       Date:  2021-02-10       Impact factor: 4.333

2.  Effect on an Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate and Vitamin D on Morphofunctional Aspects, Body Composition, and Phase Angle in Malnourished Patients.

Authors:  Isabel Cornejo-Pareja; Maria Ramirez; Maria Camprubi-Robles; Ricardo Rueda; Isabel Maria Vegas-Aguilar; Jose Manuel Garcia-Almeida
Journal:  Nutrients       Date:  2021-12-03       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.